SIM0270 clinical trials
Also written SIM0270.
How each study uses SIM0270 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SIM0270 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses SIM0270 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult ParticipantsRecruitingPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07357610Written as SIM0270
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06680921Written as SIM0270
- Evaluate the Effects of Food on the Pharmacokinetics of SIM0270CompletedPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06536036Written as SIM0270
- Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05293964Written as SIM0270
- Mass Balance Clinical Trial of SIM0270Active, not recruitingPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06654791Written as [14C] SIM0270 Oral Preparation